Pre-mobilization platelet count predicts stem cell yield during mobilization in patients with multiple myeloma
-
Published:2023-01
Issue:1
Volume:1
Page:40-45
-
ISSN:2949-7132
-
Container-title:Cancer Pathogenesis and Therapy
-
language:en
-
Short-container-title:Cancer Pathogenesis and Therapy
Author:
Chen Yuan,
Gao Shan,
Wang Yutong,
Lu Minqiu,
Chu Bin,
Shi Lei,
Xiang Qiuqing,
Fang Lijuan,
Ding Yuehua,
Wang Mengzhen,
Liu Xi,
Zhao Xin,
Sun Kai,
Bao LiORCID
Reference27 articles.
1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008
2. Multiple myeloma;Kumar;Nat Rev Dis Prim,2017
3. The role of immunomodulatory drugs in multiple myeloma;Anderson;Semin Hematol,2003
4. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial;Voorhees;Blood,2020
5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study;Moreau;Lancet,2019